Clinical Trials
37 trialsSintilimab Plus Chemotherapy as Induction Therapy for Unresectable Stage IIIC NSCLC
Sun Yat-sen University
The DoHAICs Study Expansion Phase
Tianjin Medical University Cancer Institute and Hospital
BEST
Shanghai Zhongshan Hospital
Denosumab Strategy for Liver Cancer With Bone Metastases
Tongji Hospital
Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Neoadjuvant Short-course Radiotherapy Followed by a Combination of Disitamab Vedotin, Sintilimab, and Capecitabine in Locally Advanced HER2-expressing Rectal Cance
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Radiotherapy Combined With QL1706 and Bevacizumab for Unresectable Non-metastatic Hepatocellular Carcinoma
Hebei Medical University Fourth Hospital
CISN-L
First Affiliated Hospital of Wenzhou Medical University
Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
STAR-SCLC
Second Affiliated Hospital, School of Medicine, Zhejiang University
CCGLC-018
Tongji Hospital
YOUNG-NEOS
Peking University People's Hospital
Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
PULSAR Combined With PD-1 Ab and Chemotherapy Plus Bev. for CRLM
Fujian Cancer Hospital
Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
Shanghai Zhongshan Hospital
Efficacy and Safety of Sintilimab Combined with Nab-PP Plus Rh-endostatin in Locally Advanced/advanced and Recurrent Metastatic Squamous Non-small Cell Lung Cancer: a Single-arm, Multicenter Clinical Study
Second Affiliated Hospital of Zunyi Medical University
FDZL-GC003
Fudan University
Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer
Ruijin Hospital
SPRING
Peking University Shenzhen Hospital
Peri-E
Shanghai Chest Hospital
Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma
First Affiliated Hospital of Guangxi Medical University
CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
Fudan University
Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical Trial
Shanghai Pulmonary Hospital, Shanghai, China
mRCAT-C
Sir Run Run Shaw Hospital
Example
Hunan Province Tumor Hospital
A Study on the Combination of Sintilimab, Ramucirumab and Chemotherapy for First-line Treatment of Gastric Cancer With Liver Metastasis
The First Affiliated Hospital with Nanjing Medical University
Vorolanib Plus Sintilimab for Advanced Renal Cell Carcinoma After Failure of Prior Immune Checkpoint Inhibitors Based Combination Therapy
West China Hospital
Donafenib Combine With Sintilimab and HAIC in Neoadjuvant of Resectable Hepatocellular Carcinoma
Tianjin Medical University Cancer Institute and Hospital
Conversion Therapy of Sintilimab in Combination With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherpay in Stage IV Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Adenocarcinoma
Fudan University
Eribulin Combined With Sintilimab as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Breast Cancer:A Multicenter, Single-arm,Phase II Clinical Trial
Zhejiang Cancer Hospital
PRIORITY
Ningbo No.2 Hospital
JACKPOT33
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma
Fudan University
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
Second Affiliated Hospital of Nanchang University
First-line Treatment of P53 Mutation With PD-L1 Expression in DLBCL With Anti-PD-1 Mab and R-CHOP
Innovent Biologics (Suzhou) Co. Ltd.